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Hepcidin is a main regulator of iron metabolism, of which abnormal expression affects intestinal ab-
sorption and reticuloendothelial sequestration of iron by interacting with ferroportin. It is also noted that
abnormal iron accumulation is one of the key factors to facilitate promotion and progression of cancer
including hepatoma. By RT-PCR/agarose gel electrophoresis of hepcidin mRNA in a hepatocellular car-
cinoma cell line HLF, a smaller mRNA band was shown in addition to the wild-type hepcidin mRNA. From
sequencing analysis, this additional band was a selective splicing variant of hepcidin mRNA lacking exon
2 of HAMP gene, producing the transcript that encodes truncated peptide lacking 20 amino acids at the
middle of preprohepcidin. In the present study, we used the digital PCR, because such a small amount of
variant mRNA was difﬁcult to quantitate by the conventional RT-PCR ampliﬁcation. Among seven
hepatoma-derived cell lines, six cell lines have signiﬁcant copy numbers of this variant mRNA, but not in
one cell line. In the transient transfection analysis of variant-type hepcidin cDNA, truncated pre-
prohepcidin has a different character comparing with native preprohepcidin: its product is insensitive to
digestion, and secreted into the medium as a whole preprohepcidin form without maturation. Loss or
reduction of function of HAMP gene by aberrantly splicing may be a suitable phenomenon to obtain the
proliferating advantage of hepatoma cells.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepcidin is a central iron regulator derived from hepatocytes, of
which function is to inhibit both enteric absorption and reticulo-
endothelial sequestration of iron through binding to ferroportin
[1,2]. Its gene is called as HAMP, and composed of 3 exons and 2
introns in between, and the mature mRNA of hepcidin is formed by
splicing [3]. As hepatocyte is a major organ of hepcidin production,
the mature form of hepcidin, hepcidin-25 detected in serum isintestinal Immunology and
rsity, 2-1-1-1, Midorigaoka-
Sasaki).
Inc. This is an open access article uthought to reﬂect the status of body iron storage and inﬂammation
[4]. Until now, there are couple of reports that the expression of
hepcidin was altered in various types of diseases representing
anemia of inﬂammation, although there were few studies investi-
gating the expression of hepcidin in hepatocellular carcinoma
(HCC). Studies using liver biopsy and surgical samples of HCC
revealed that the expression of hepcidin mRNA was down-
regulated in the tumorous tissues compared to the adjacent non-
tumorous liver tissues [5e8]. Although the mechanism respon-
sible for suppression of hepcidin mRNA expression remains un-
clear, this phenomenon may be advantageous for the growth of
tumor cells, because duodenal enterocytes transfer iron to plasma
is increased and resulted in an increase of body iron for cell growth
by reduction of hepcidin. On the other hand, hepcidin mRNAnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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such as IL-6, IL-1b and interferon a by invaded macrophages sur-
rounding the tumors, which is the major cause of anemia of
inﬂammation [9e11].
We previously demonstrated that there were differences in the
expression of hepcidin mRNA among 12 kinds of cell lines derived
from HCC by quantitative RT-PCR. Furthermore, there were unex-
pected differences in the secretion of hepcidin isoforms hepcidin-
20, -22 and -25 among these HCC-derived cells by simultaneous
quantiﬁcation using liquid chromatography/selected reaction
monitoring tandem mass spectrometry (LC-MS/MS) [12]. Con-
cerning the mechanism of hepcidin regulation, a single nucleotide
deletion of hepcidin mRNA, an elongated abnormal polypeptide, a
new stop codon, and a decreases of transcriptional activity have
been postulated [13e15]. However, up until now, the splicing
variant of HAMP transcript have not been reported, of which form is
common in transcripts of HFE, another regulatory molecule of iron
metabolism [16].
By conventional RT-PCR/agarose gel electrophoresis for detect-
ing a wild-type HAMP transcript, we found a new smaller hepcidin
mRNA lacking an exon 2 of HAMP gene in HCC-derived cell line HLF.
Then, by sensitive digital PCR using speciﬁc probes to this variant,
we found that most of HCC-derived cell lines have signiﬁcant copy
numbers of hepcidin mRNAvariant. Furthermore, we examined the
molecular form secreted from cells by using the transient trans-
fection analysis of variant-type hepcidin cDNA.
2. Materials and methods
2.1. Cell culture
293T was purchased from GenHunter Co. (Nashville, TN). HCC-
derived cell lines, HepG2, Hep3B, HuH7, WRL68 and SK-HEP-1
were commercially obtained from DS Pharma Biomedical Co.
(Osaka, Japan). HLE and HLF were supplied from the Health Science
Research Resources Bank (Osaka, Japan).
2.2. First strand cDNA synthesis and polymerase chain reaction (RT-
PCR)
RT-PCR was performed using PrimeScript™ RT and TaKaRa Ex
Taq® HS (Takara Bio, Ohtsu, Japan). Primers speciﬁc from the start
and the stop codon were used; forward primer: 50-ATGGCACT-
GAGCTCCCAGAT-30, reverse primer: 50-CTACGTCTTGCAGCACATCC-
3’ (bold characters indicate start and stop codons, respectively).
2.3. Absolute quantiﬁcation of hepcidin mRNA by digital PCR
For more sensitive and absolute quantiﬁcation of hepcidin
mRNA in cells, QuantStudio™ 3D Digital PCR System (Applied
Biosystems®, Thermo Fisher Scientiﬁc, Waltham, MA) was used
[17]. The PCR ampliﬁcation was performed using a set of primers
and the speciﬁc probe to variant-type hepcidin mRNA. First strand
cDNA was synthesized using PrimeScript™ RT. PCR ampliﬁcation
was performed with QuantStudio™ 3D digital PCR master mix, on
following cycle conditions: cycle 1, 96 C for 10 min; cycle 2e39,
60 C for 2min, 98 C for 30 s; and ﬁnal step at 60 C for 2min,10 C
inﬁnitely.
2.4. Construction of preprohepcidin expression plasmids
Wild-type and variant-type preprohepcidin cDNA fragments
were inserted into the mammalian expression plasmid, pCAcc [18].
Wild-type and variant-type preprohepcidin cDNA fragments
without stop codon were cloned into the multi-cloning site of twotags containing plasmid, pcDNA™3.1()/myc-His/version A (invi-
trogen™, Thermo Fisher Scientiﬁc) in frame with these tags to
create a fusion peptide in a C-terminus [19]. Each fragments of myc-
His tagged preprohepcidin cDNAwere separated and inserted back
to the pCAcc plasmid.
2.5. Quantiﬁcation of hepcidin isoform
293T cells were transfected with wild-type and variant-type
preprohepcidin expression plasmids, respectively. 24 h and 48 h
later, conditioned media were collected, and hepcidin isoforms
were measured by LC-MS/MS as our previous report [12].
2.6. Western blot analysis
293T cells were transfected with pCAHAMP-myc-His, and
pCA△HAMP-myc-His, respectively. 48 h later, conditioned media
were collected, and these supernatants were incubated with 80 ml
of Ni-NTA agarose suspension (Qiagen, Hilden, Germany) for 16 h at
4 C. Pull-down polypeptides were eluted from Ni-NTA agarose by
boiling for 5 min at 95 C in 1  Tricine sample buffer (Bio-Rad,
Hercules, CA) with 2%(v/v) b-mercaptoethanol. Samples were
separated by tricine-SDS/PAGE in 16.5% gels by the method of
Sch€agger and von Jagow [20], and were transferred onto
Immobilon-P SQ (Merck Millipore, Darmstadt, Germany). The blot
was incubated with rabbit anti-myc tag antibody and anti-rabbit
antibody conjugated with HRP, following with SuperSignal™
West Dura Extended Duration Substrate (Thermo Fisher Scientiﬁc).
3. Results
3.1. Identiﬁcation of variant-type hepcidin mRNA
Hepcidin mRNA expression in a HCC-derived cell line, HLF was
examined by using RT-PCR and agarose gel electrophoresis. The use
of 2 primers complementary to the start and the stop codon regions
was allowed the ampliﬁcation of the predicted coding region of full
length hepcidin mRNA. In electrophoresis, an amplicon of sourcing
the full-length of preprohepcidin was detected (Fig. 1A). Interest-
ingly, an additional band smaller than the full length size was ob-
tained, suggesting that this amplicon was sourced from a variant
formed mRNA. We then cloned and sequenced the corresponding
two RT-PCR products. One was the correctly spliced full length
transcript of 255 bp fragment (Fig. 1B). Another was the smaller
one, which was identical to the wild-type preprohepcidin sequence
except lacking of an internal 60 bp fragment in the NCBI Gene
Reference NM_0221175.3 (Fig.1C).We named this smaller fragment
as DHAMP. In this alternative transcript, exon 2 is skipped without
generating the frameshift and amino acid change in the new exon 1
e exon 3 junction.
3.2. Absolute quantiﬁcation of variant-type hepcidin mRNA
In the present study, we used absolutely attainable chip-based
digital PCR (digital PCR), because such small amount of variant-
type hepcidin mRNA was difﬁcult to quantitate in the conven-
tional RT-PCR ampliﬁcation. Furthermore, the quantitation of
endpoint-amplicons separated on the agarose gel electrophoresis
was not satisfactory [21]. From these reasons, to conﬁrm this
variant in HCC-derived cell lines, we performed the digital PCR to
access the exact expression level of variant-type hepcidin mRNA by
a speciﬁc probe.
To detect a wild-type hepcidin mRNA, the forward primer was
designed to bind in the region of exon 1 and the reverse primer was
designed to bind in the region of exon 2 (Fig. 2A). When wild-type
Fig. 1. Identiﬁcation of an alternative splicing in the HAMP gene. (A) Expression of hepcidin mRNA in hepatocellular carcinoma cell line HLF was analyzed by RT-PCR, and products
were run on 2% NuSieve™ GTG™ agarose gel/TAE. (B) Sequencing electrophoretogram of PCR product was shown each location of exon 1 e exon 2 and exon 2 e exon 3 junctions of
wild-type hepcidin mRNA. (C) The location of a new exon 1 e exon 3 junction of variant-type hepcidin mRNA. Schematic organizations were indicated human HAMP gene and
transcripts.
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Fig. 2. Absolute quantiﬁcation of hepcidin mRNA. (A) Primers and probes used in a chip-based digital PCR assays. (B) PCR ampliﬁcations were performed using each wild-type
hepcidin cDNA and variant-type hepcidin cDNA as templates, and amplicons were resolved on agarose gel electrophoresis. (C) Absolute quantiﬁcation of wild-type and variant-
type hepcidin mRNAs in HCC-derived cell lines by digital PCR.
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the size was ampliﬁed. On the other hand, an amplicon for variant-
type hepcidin mRNA was not detected, because the reverse primer
targeting to exon 2 could not anneal to variant-type hepcidinmRNA
lacking the exon 2 region (Fig. 2B). To detect a variant-type hepcidin
mRNA, the forward primer was designed to bind in the region of
exon 1 and the reverse primer was designed to bind in the region of
exon 3 (Fig. 2A). When variant-type hepcidin mRNA was included
in a sample, a 67 bp band was ampliﬁed. In addition, the amplicon
for wild-type hepcidin mRNA in the same sample was detected as a
127 bp band, because the reverse primer targeting to exon 3 can
anneal to wild-type hepcidin mRNA, too (Fig. 2B). From these rea-
sons, speciﬁc probes for the detection of each amplicon of wild-
type and variant-type hepcidin mRNAs were necessary in this
assay. These speciﬁc probes were designed for wild-type hepcidin
mRNAwhich is bound at the original junction of exon 1 and exon 2,
and for variant-type hepcidin mRNA which is bound at the new
junction of exon 1 and exon 3, respectively (Fig. 2A). Fig. 2C shows
the copy number/mg RNA of wild-type and variant-type hepcidin
mRNAs. We detected variant-type hepcidin mRNA in 6 of 7 cell
lines; HepG2 (538.1 copy numbers/mg RNA), HuH7 (988.1 copy
numbers/mg RNA), HLE (9.9 copy numbers/mg RNA), HLF (4.4 copy
numbers/mg RNA), WRL68 (31.2 copy numbers/mg RNA) and SK-
HEP-1 (27.1 copy numbers/mg RNA), but not in Hep3B (0 copy
number/mg RNA). In the assays of wild-type mRNA, two cell lines
have higher expressions (66,036.6 copy numbers/mg RNA in HepG2
and 167,810.0 copy numbers/mg RNA in HuH7) and other ﬁve cell
lines have lower expressions (93.6 copy numbers/mg RNA in Hep3B,
0.5 copy number/mg RNA in HLE, 1.5 copy numbers/mg RNA in HLF,
2.8 copy numbers/mg RNA inWRL68, and 2.3 copy numbers/mg RNA
in SK-HEP-1).
3.3. Detection of mature hepcidin-25 translated from variant-type
hepcidin mRNA
To evaluate whether mature hepcidin-25 is produced from
variant-type hepcidin mRNA, transient transfection was conducted
to collect the conditioned medium containing any secreted hepci-
din. Schematic diagrams of the structure of hepcidin expression
plasmids and expected polypeptides translated from each plasmid
were shown in Fig. 3A and B.
The hepcidin-25 values in the conditioned medium from 293T
cells transfected with wt HAMP cDNAwere increased progressively
from 53.6 ng/ml at 24 h to 193.9 ng/ml at 48 h. On the other hand,
the hepcidin-25 values in the transfection with DHAMP cDNAwere
low; 2.3 ng/ml at 24 h and 4.1 ng/ml at 48 h, respectively (Fig. 3C).
This result shows that mature hepcidin-25 is not generated efﬁ-
ciently from variant-type hepcidin mRNA. In addition, hepcidin
isoforms; hepcidin-20 and -22 in the conditioned medium from
293T cells transfected with wt HAMP cDNAwas detected, but not in
the transfection of DHAMP cDNA (Fig. 3D).
3.4. Identiﬁcation of secreted polypeptide form by variant-type
hepcidin mRNA
To identify which polypeptides are secreted in the culture me-
dium from variant-type hepcidin mRNA, transient transfection and
pull-down assayswere conducted. The expression plasmids of myc-
His tagged preprohepcidin were schemed in Fig. 4A, and expected
polypeptides from each myc-His tagged hepcidin cDNA were
translated in Fig. 4B.
In the transfection of wtHAMP cDNA, in addition to the expected
size length (12.3 kDa) of preprohepcidin-myc-His (triple arrow-
heads in Fig. 4C), two signals at 9.8 kDa (double arrowheads) and5.7 kDa (single arrowhead) were detected in the spent medium;
these predicted molecular weights correspond to prohepcidin-
myc-His and hepcidin-25-myc-His, respectively. From this result,
it was elucidated that the addition of myc-His tag to the C-terminal
site of preprohepcidin had no inﬂuence in the posttranslational
processes. On the other hand, in the transfection of a plasmid car-
rying DHAMP cDNA fused with the code for myc-His tag, a single
band corresponding to the predicted molecular weight for trun-
cated preprohepcidin-myc-His (10.1 kDa) was pull-downed from
the spent medium (asterisk in Fig. 4C). Thus, most part of this
truncated preprohepcidin-myc-His was secreted from the cell
without posttranslational cleavage.
4. Discussion
In this work, we found an alternative HAMP transcript in HCC-
derived cell line, HLF, demonstrating that this transcript is a novel
variant-type hepcidin mRNA encoding exon 2-lacked pre-
prohepcidin. Furthermore, it was revealed that six of seven HCC-
derived cell lines have a signiﬁcant copy numbers of this variant
by a digital PCR.
On the expression studies of hepcidin mRNA using liver biopsy
and surgical samples of HCC revealed, it was generally down-
regulated in the tumorous tissues compared to the adjacent non-
tumorous liver tissues by using the pair of primers targeting hep-
cidin mRNA [5e8]. In two assays [5,6], the forward primer designed
to exon 1 region of hepcidin mRNA, and the reverse primer to exon
3 region of that, and SYBR Green I inter-chelating reagent for
detecting amplicons were used in real-time PCR. According to these
primer structures, the level of hepcidin mRNA was estimated as a
sum of hepcidin mRNA of wild-type mRNA and variant-type mRNA
if any. In other two studies [7,8], the pair of primers targeting
hepcidin mRNA were designed to exon 1e2 boundary and exon 3
regions respectively, the probe was only hybridized to wild-type
hepcidin mRNA.
In the present study, we initially used the common primers
located in exon 1 and exon 3, and we accidentally noticed the
smaller band of abnormal splicing on one HCC-derived cell line HLF
in agarose gel electrophoresis. By sequencing analysis of this
smaller band, we found that this mRNA encodes the exon 2-lacked
preprohepcidin. We therefore speculated that the conventional
assay using these probes may miss the variant-type hepcidin
mRNA. In order to dissolve these problems of hepcidin mRNA
quantiﬁcation, we concluded that speciﬁc probes of each amplicon
of wild-type and variant-type hepcidin mRNAs are necessary for
the detection in each assay. As shown in Fig. 2A, we constructed
probes speciﬁc to wild-type and variant-type hepcidin mRNAs,
respectively. In addition, a small amount of variant-type hepcidin
mRNA was considered to be difﬁcult to quantitate by the conven-
tional RT-PCR ampliﬁcation, and therefore the digital PCR was
selected, which is more sensitive than the conventional RT-PCR
ampliﬁcation and enable to absolute quantiﬁcation (copy
numbers/mg RNA) in a sample [17].
Accordingly, six of seven HCC-derived cell lines; HepG2, HuH7,
HLE, HLF, WRL68 and SK-HEP-1, but not Hep3B, expressed variant-
type hepcidin mRNA between 4.4 and 988 copy numbers/mg RNA,
while all the HCC-derived cell lines expressed wild-type hepcidin
mRNA between 0.5 and 167,810 copy numbers/mg RNA. In the as-
says of wild-type mRNA, two cell lines have higher expressions and
others have lower expressions, which may be consistent to previ-
ous reports that the expression of hepcidin mRNA was down-
regulated in most of HCC [5e8].
Because human genes typically contain multiple introns, the
process of pre-mRNA splicing is an essential step in the expression
Fig. 3. Quantiﬁcation of hepcidin isoforms secreted from cells. (A) Schematic diagram of a recombinant plasmid expressing preprohepcidin. (B) Amino acid sequences of pre-
prohepcidin (adapted from reference no. 3), and truncated preprohepcidin which is removed the region from codon 31 to codon 50, respectively. (C) Conditioned media fromwhich
293T cells were transiently transfected with HAMP cDNA, were collected and hepcidin-25 were measured by LC-MS/MS. no plasmid, non-transfected 293T cells; mock, original
plasmid pCAcc; wtHAMP cDNA, full-length preprohepcidin cDNA (pCAHAMP); DHAMP cDNA, preprohepcidin cDNA lacked an internal 60 bases (pCADHAMP); n.d., not detected. (D)
Quantiﬁcation of hepcidin isoforms in conditioned media at 48 h after transfections.
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synthesis of multiple mRNAs encoding different proteins from a
single gene [16]. The choice of alternative splicing pattern is often
tissue speciﬁc, and can profoundly affect the activity of the encoded
peptide [23]. An alternatively spliced exon is generally under the
control of multiple splicing regulators [24]. In our analysis, any
mutations, deletions and insertions were not found in three exons
and two introns encompassing the full region of HAMP gene (NCBI
Reference Sequence: NG_011563.1) in HLF cell line. This splicing
variant does not ﬁt with any mechanism resulting from known
splicing consensus sequences [25]. In addition, variant-type hep-
cidin mRNA might not be subjected to nonsense-mediated decay
(NMD) that is believed to be a mechanism for proofreading of
transcripts to prevent the inappropriate expression of aberrant
proteins [26]. Therefore, we speculated that variant-type hepcidin
mRNA escaped from NMD. Furthermore, whole-exome sequenc-
ings revealed that any predominant mutation on the component
genes of the RNA splicing machinery was not found in the all seven
cell lines.
To clarify the characteristic features of a new peptide from
variant-type hepcidin mRNA, we used the transient transfection to
293T cells, in which there was no detectable level of HAMP tran-
scripts and mature hepcidin-25 under the conventional culture
condition. In the western blot analysis of pull-down-extracts from
the spent medium, we detected three bands corresponding to the
predicted molecular weights for preprohepcidin-myc-His, pro-
hepcidin-myc-His and hepcidin-25-myc-His, respectively. In otherwords, when 293T cells were transfected with the expression
plasmid of myc-His tagged wild-type preprohepcidin, the myc-His
tagged preprohepcidin produced in 293T cells was correctly pro-
cessed. Nevertheless, from spent medium of 293T cells over-
expressed with the truncated preprohepcidin-myc-His, most part
of peptides was secreted from cells without the posttranslational
processing. In addition, when 293T cells were transfected with the
expression plasmid of tag-free truncated preprohepcidin, the level
of mature hepcidin-25 in the culture medium was very low
comparing to that in wild-type preprohepcidin transfection. From
these results, 20 amino acids residues comprising exon 2 in the
HAMP gene which are located between the secretory signal peptide
and the motif peptide of proprotein convertase, will be regarded as
structural residues that participate in maintaining the scaffold
which only limited enzymes can attach and work. In contrast to
normal cells, aberrantly splicing variants may lead to loss or
reduction of function of these genes in cancer, and these are suit-
able phenomena for the growth of cancer cells [27,28].
In summary, our paper is the ﬁrst to demonstrate that there was
an aberrant splicing from of the HAMP gene, producing the tran-
script that encodes truncated peptide lacking 20 amino acids at the
middle of preprohepcidin. This alternative transcript results in a 64
aa truncated preprohepcidin: its product is insensitive to digestion,
and secreted from cells as a whole molecule form without matu-
ration. Further work is required to identify the physiological and/or
pathological situations where variant-type hepcidin mRNA might
be expressed, and to evaluate its role.
Fig. 4. Analysis of polypeptides secreted from cells. (A) Schematic diagram of a recombinant plasmid expressing myc-His tagged preprohepcidin. (B) Amino acid sequences of myc-
His tagged preprohepcidin and truncated preprohepcidin, respectively. (C) Conditioned media fromwhich 293T cells were transiently transfected with HAMP cDNA, were collected
and secreted polypeptides tagged with myc-His were analyzed by Western blotting. no plasmid, non-transfected 293T cells; mock, original plasmid pCAcc; wtHAMP cDNA, full-
length myc-His tagged preprohepcidin cDNA (pCAHAMP-myc-His); DHAMP cDNA, myc-His tagged preprohepcidin cDNA lacked an internal 60 bases (pCADHAMP-myc-His);
n.d., not detected. 888, preprohepcidin-myc-His; 88, prohepcidin-myc-His; 8, hepcidin-25-myc-His; ✩, truncated preprohepcidin-myc-His.
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